Comparative efficacy of quarterly vs. monthly triptorelin in Chinese girls with central precocious puberty: a 12-month observational study

Background: This study aimed to compare the clinical efficacy of quarterly (15 mg/90 days) versus monthly (3.75 mg/28 days) triptorelin formulations with respect to bone maturation, predicted adult height (PAH), and hormonal suppression in Chinese girls with central precocious puberty (CPP). Methods: = 38). The evaluated outcomes included bone age (BA; TW3 method), PAH, serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) concentrations, uterine and ovarian volumes, body mass index (BMI), and adverse events, assessed at baseline, 6 months, and 12 months. Results: = 0.008), with no significant differences between regimens. Three patients experiencing a "flare-up" had a larger mean baseline uterine volume (6.95 mL) compared with the remaining 67 patients (2.38 mL). Conclusion: Quarterly triptorelin demonstrated efficacy comparable to that of monthly administration in suppressing puberty and improving PAH in Chinese girls with CPP.